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988Contemporary outcomes of endovascular
interventions for acute limb ischemia
Raphael M. Byrne, BA,a Ashraf G. Taha, MD,a,b Efthymios Avgerinos, MD,a Luke K. Marone, MD,a
Michel S. Makaroun, MD,a and Rabih A. Chaer, MD,a Pittsburgh, Pa; and Assiut, Egypt
Objective: Thrombolysis as a treatment for acute limb ischemia (ALI) has become a ﬁrst-line therapy based on studies
published over 2 decades ago. The purpose of this study was to assess outcomes of patients treated for ALI using
contemporary thrombolytic agents and endovascular techniques.
Methods: Consecutive patients with ALI of the lower extremities treated between 2005 and 2011 were identiﬁed, and
their records were retrospectively reviewed. All patients were treated with tissue plasminogen activator delivered via
catheter-directed thrombolysis (CDT) and/or pharmacomechanical thrombolysis (PMT), with other adjunctive
endovascular or surgical interventions. Procedural success, thrombolysis duration, and 30-day and long-term outcomes
were obtained for the whole series and were also compared between the CDT and PMT groups. Limb salvage and
survival were assessed using time-to-event methods, including Kaplan-Meier estimation and Cox proportional hazards
models.
Results: A total of 154 limbs were treated in 147 patients presenting with ALI (Rutherford class I, 9.7%; class IIa,
70.1%; class IIb, 20.1%). The mean follow-up was 15.20 months (range, 0.56-56.84 months). Indications for inter-
vention included embolization (14.3%), thrombosed bypass (36.4%), thrombosed stent (26.6%), native artery
thrombosis (24.0%), and thrombosed popliteal aneurysm (3.2%). Technical success was achieved in 83.8% of cases, with
a 30-day mortality rate of 5.2%. Procedural complications included systemic bleeding (5.2%), access site hematoma
(4.5%), acute renal failure (1.9%), and distal embolization (9.7%). The mean runoff score decreased from 13.42 pre-
intervention to 7.43 postintervention. Adjuvant revascularization procedures were required in 89.0% of patients and
were endovascular (68.8%), hybrid (9.1%), or open (11.0%). Only 3.2% of patients required a fasciotomy. The overall
rate of major amputation was 15.0% (18.1% for CDT only, 11.3% for PMT; P [ NS). Predictors of limb loss by Cox
proportional hazards models included end-stage renal disease (hazard ratio [HR], 8.563; P < .001) and poor pedal
outﬂow, with an incremental protective effect for improved pedal outﬂow (HR, 0.205; P < .001 for one pedal outﬂow
vessel; HR, 0.074; P < .001 for $ two pedal outﬂow vessels). Gender, smoking, diabetes, Rutherford score, runoff
score, thrombosed popliteal aneurysm, and PMT were not signiﬁcant predictors of limb loss. The use of PMT was
a signiﬁcant predictor of technical success (odds ratio, 2.67; P [ .046).
Conclusions: Endovascular therapy with thrombolysis using tissue plasminogen activator remains an effective treatment
option for patients presenting with mild or moderate lower extremity ALI, with equal beneﬁt derived with CDT or PMT.
Patients with end-stage renal disease or poor pedal outﬂow have an increased risk of limb loss and may beneﬁt from
alternative revascularization strategies. (J Vasc Surg 2014;59:988-95.)The use of catheter-directed thrombolysis (CDT) to
treat acute limb ischemia (ALI) has become part of routine
clinical care in the past 2 decades, following the publication
of two large randomized controlled trials (Surgery Versus
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[TOPAS]) that demonstrated at least equal efﬁcacy
compared with open surgical thrombectomy.1,2 Since the
publication of these trials, thrombolysis has evolved such
that current thrombolytic therapy and techniques differ
signiﬁcantly from those studied in the trials. One signiﬁcant
difference is the lytic agent used. Almost all patients
enrolled in STILE and TOPAS received urokinase, while
the most common lytic agent used in current practice is
tissue plasminogen activator (tPA). Another important
difference is the use of pharmacomechanical thrombolysis
(PMT), which is commonly used in current practice but
was not utilized in STILE or TOPAS. PMT combines
mechanical energy with the thrombolytic infusion to
actively break and dissolve thrombus. It has been shown
to allow for faster clot dissolution than CDT, but it may
also confer greater bleeding and distal embolization risks.3
In light of the evolution of endovascular therapy for
the treatment of ALI, with different devices and pharmaco-
logic agents currently in use, it is unclear if favorable
outcomes continue to be achieved. The objectives of our
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with ALI treated with current endovascular techniques,
and to speciﬁcally compare the outcomes of patients
treated with CDT and those treated with PMT.
METHODS
Following approval by the institutional review board,
a retrospective, single-institutional review was performed
using a prospectively maintained vascular registry.
Patients
All patients with lower extremity ALI treated with
thrombolysis at the University of Pittsburgh hospitals
between 2005 and 2011 were included in the study. All
clinical data were obtained from the electronic medical
record. Preprocedural data collected included patient
demographics, comorbidities, etiology and location of
thrombosis, and previous ipsilateral revascularization.
Initial limb evaluation
Limb condition on presentation, including sensory and
motor deﬁcits, rest pain, poikilothermy, and ischemic ulcer-
ation were recorded, and each limb was scored according
to the Rutherford classiﬁcation scale.4 The anatomic extent
of the thrombosis and the variability in the runoff were
gauged by using the modiﬁed Society for Vascular Surgery
(SVS) runoff score and the pedal runoff score.5,6
Themodiﬁed SVS runoff scorewas calculated both at the
initiation and completion of the procedure using stored
angiographic images.4,5 This score ranged from 0 to 19,
with a higher score indicating more severe disease. It was
calculated by assessing the patency and degree of stenosis/
occlusion in the popliteal artery and the tibial vessels. A score
of 0 was assigned to a vessel with<20% stenosis, a score of 1
for a 21% to 49% stenosis, 2 for 50% to 99% stenosis, 2.5 for
a vessel occluded over an area less than half its length, and 3
for an occlusion greater than half the vessel length.5 The
score for the popliteal was multiplied by three before adding
all four vessel scores together.
The pedal runoff was evaluated angiographically at the
initiation of thrombolysis by assessing the patency of the
dorsalis pedis, posterior tibial, and peroneal collateral
vessels in the foot. A pedal runoff score was assigned by
giving one point for each patent pedal vessel, for
a maximum score of 3 and a minimum score of 0.6
Procedures
Patients were divided into two groups based on the
endovascular treatment modality used: CDT alone and
PMT with or without CDT. Any patient receiving PMT
(with or without adjunctive CDT) was classiﬁed in the
PMT group. Recombinant tissue plasminogen activator
(rtPA; Genentech, Inc, San Francisco, Calif) was used in
all patients, and the dose ranged from 0.25 to 1.00 mg/
hr. The technique used (CDT vs PMT) was at the opera-
tor’s discretion. In general, PMT was more likely to be
used in fresh clot that was <2 weeks old, primarily
in thrombosed femoropopliteal stents, or for residualthrombus after CDT. PMT was typically avoided in tibial
vessels. Technical success was deﬁned in both the PMT
and CDT groups as the ability to restore inline ﬂow to
the foot without requiring immediate surgical conversion.
Restoration of ﬂow to a patent peroneal to the ankle or
to large collaterals that were believed to be the baseline
outﬂow vessels were also considered technical successes.
Adjunctive procedures with angioplasty or stenting were
performed as needed. In cases of stent thrombosis, causa-
tive lesions were treated with a variety of techniques
following successful lysis. These included simple or
cutting-balloon angioplasty, overstenting with bare metal
stents for residual stenosis or ﬂow-limiting dissection after
angioplasty, and overstenting with heparin-bonded Via-
bahn stents (Gore Medical, Flagstaff, Ariz). Postprocedure
surveillance was performed in accordance with our previ-
ously published protocol.7
CDT. Standard wire and catheter techniques were
utilized to cross the thrombosed arterial segment. Selective
injection beyond the thrombus was performed to conﬁrm
a patent distal lumen and to image the runoff. CDT was
delivered using a multisidehole catheter (Cragg McNa-
mara; ev3 Endovascular Inc, Plymouth, Minn or Unifuse;
Angiodynamics, Latham, NY). The length of the infusion
segment of lysis catheter was chosen to cover the full extent
of the thrombus. In patients with thrombus extension into
the tibial runoff, a coaxial system was utilized by placing
a Katzen infusion wire (Boston Scientiﬁc, Natick, Mass)
through the multisidehole catheter into the thrombosed
tibial. Prior to the initiation of lytic infusion, a bolus of
2 mg of tPA was delivered into the thrombus. Therapeutic
anticoagulation was not maintained during the lytic infu-
sion, and an unfractionated heparin drip was used through
the access sheath at a rate of 500 units/hour. Heparin was
delivered coaxially in all patients. A follow-up angiogram
was typically performed at 8- to 12-hour intervals
following initiation of lytic therapy, to check on the results
of the thrombolysis and need for additional interventions.
PMT. PMT was delivered using the Angiojet Xpeedior
catheter (MEDRAD, Inc, Warrendale, Pa). It was initially
used in power pulse mode with 6- to 10-mg tPA, and
was reactivated in regular thrombectomy mode after a dwell
time of 12 to 15 minutes. The runoff was routinely thor-
oughly reimaged after PMT to assess for embolization. A
combination of PMT and CDT was used in patients with
suboptimal initial PMT requiring additional lysis via
CDT, or patients with residual clot following CDT
requiring additional lysis via PMT. This decision for combi-
nation therapy was made based on angiographic ﬁndings at
the time of treatment. PMT may have been avoided by
some operators as ﬁrst-line therapy in patients with pros-
thetic bypass grafts because of a perceived increased risk for
embolization, but this was not a general algorithm that was
followed by the group.
Outcomes
The primary end points evaluated were limb salvage, pri-
mary patency, primary assisted patency, secondary patency,
Table I. Baseline demographics and characteristics on a per-limb basis
CDT (n ¼ 83), No. (%) PMT (n ¼ 71), No. (%) Overall (n ¼ 154), No. (%) P value
Mean age, years 65.53 65.35 65.45 .943
Gender (female) 34 (41.0) 31 (43.7) 65 (42.2) .746
Smoking .389
Never smoker 25 (30.1) 15 (21.1) 40 (26.0)
Current smoker 36 (43.4) 32 (45.1) 68 (44.2)
Former smokera 21 (25.3) 23 (32.4) 44 (28.6)
Hypertension 62 (74.7) 54 (76.1) 116 (75.3) .843
Hypercholesterolemia 36 (43.4) 30 (42.3) 66 (42.9) .870
Diabetes 34 (41.0) 25 (35.2) 59 (38.3) .504
CAD 44 (55.0) 39 (54.9) 83 (53.9) .870
CABG 19 (22.9) 20 (28.2) 39 (25.3) .575
CHF 17 (20.5) 14 (19.7) 31 (20.1) .886
COPD 22 (26.5) 13 (18.3) 35 (22.7) .248
Atrial ﬁbrillation 21 (25.3) 12 (16.9) 33 (21.4) .239
Stroke 9 (10.8) 10 (14.1) 19 (12.3) .626
Cancer 16 (19.3) 19 (26.7) 35 (22.7) .334
Baseline Cr >1.2 17 (20.5) 16 (22.5) 33 (21.4) .843
ESRD 3 (3.6) 4 (5.6) 7 (4.5) .704
Previous ipsilateral revascularization
Femoral-popliteal PTA/stent 14 (16.9) 22 (31.0) 36 (23.4) .055
Iliac PTA/stent 9 (10.8) 8 (11.3) 17 (11.0) .933
Femoral-popliteal bypass (prosthetic) 8 (9.6) 19 (26.8) 27 (17.5) .010b
Femoral-popliteal bypass (vein) 9 (10.8) 3 (4.2) 12 (7.8)
Femoral-tibial bypass (prosthetic) 9 (10.8) 7 (9.9) 16 (10.4) .975b
Femoral-tibial bypass (vein) 1 (1.2) 1 (1.4) 2 (1.3)
Rutherford score on presentation
I 8 (9.6) 7 (9.9) 15 (9.7) .99
IIa 58 (69.9) 50 (70.4) 108 (70.1)
IIb 17 (20.5) 14 (19.7) 31 (20.1)
III 0 (0.0) 0 (0.0) 0 (0.0)
CAD, Coronary artery disease; CABG, coronary artery bypass graft; CDT, catheter-directed thrombolysis; CHF, congestive heart failure; COPD, chronic
obstructive pulmonary disease; Cr, serum creatinine; ESRD, end-stage renal disease; PMT, pharmacomechanical thrombolysis; PTA, percutaneous trans-
luminal angioplasty.
aQuit at least 1 year prior to presentation.
bThis P value compares no bypass vs prosthetic bypass vs vein bypass.
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bolysis, each limb was analyzed independently. In limbs
that required multiple revascularizations, the ﬁrst per-
formed endovascular revascularization procedure was
treated as the index procedure, and patency rates were
calculated accordingly. Patency rates were determined
according to SVS guidelines.4 Primary patency applied
to a vessel or graft that remained patent after the initial
procedure without requiring additional intervention.
Primary assisted patency applied when a vessel or graft
required an additional intervention but remained patent.
Secondary patency referred to revascularization after
a complete occlusion of the vessel or graft. Secondary
patency for each intervention was achieved using repeat
endoluminal intervention to recanalize occluded arterial
segments or by performing hybrid procedures or open
surgical bypass. In those patients who needed a subse-
quent surgical bypass, any patency was considered lost
at the time the decision for bypass was made. An overall
major amputation rate was calculated using any above- or
below-knee amputation that occurred during the study
period and included both periprocedural and longer-
term amputations. A periprocedural major amputationrate was also calculated at both 30 days and 12 months
postprocedure. The Social Security Death Index database
was used to assess long-term mortality.
Statistical analysis
Patient demographics and comorbidities were compared
between the two groups using the c2 test for categorical vari-
ables and the t-test for continuous variables. The primary end
points of patency, mortality, and freedom from amputation
were assessed using the Kaplan-Meier method and were
compared using log-rank tests. Multivariable analysis was per-
formed using Cox proportional hazards regression models.
All analysis was performed with SAS Version 9.2 (SAS Insti-
tute Inc, Cary, NC) and Stata Version 11 (StataCorp LP,
College Station, Tex). All analyses were performed by the
biostatistics core of the University of Pittsburgh Clinical
and Translational Science Institute.
RESULTS
A total of 154 limbs in 147 patients were included in
the study. Eighty-three limbs received CDT only (CDT
group), 15 received PMT only, and 56 received a combina-
tion of CDT and PMT for a total of 71 limbs in the PMT
Table II. Etiology of ischemiaa
CDT
(n ¼ 83),
No. (%)
PMT
(n ¼ 71),
No. (%)
Overall
(n ¼ 154),
No. (%)
P
value
In situ thrombosis 21 (25.3) 16 (22.5) 37 (24.0) .710
Failed stent 18 (21.7) 23 (32.4) 41 (26.6) .147
Failed bypass 30 (36.1) 26 (36.6) 56 (36.4) .951
Thrombosed
popliteal
aneurysm
4 (4.8) 1 (1.4) 5 (3.2) .677
Embolization 16 (19.3) 6 (8.5) 22 (14.3) .066
CDT,Catheter-directed thrombolysis; PMT, pharmacomechanical thrombolysis.
aSome cases had multiple etiologies of ischemia: four cases were due to
a combination of failed bypass and failed stent, one case was due to failed
bypass with separate in situ thrombosis, one case was due to a failed stent
with separate in situ thrombosis, and one case was due to a thrombosed
popliteal aneurysm with separate in situ thrombosis.
Table III. Complications
CDT
(n ¼ 83),
No. (%)
PMT
(n ¼ 71),
No. (%)
Overall
(n ¼ 154),
No. (%)
P
value
Systemic bleed 3 (3.6) 5 (7.0) 8 (5.2) .34
Acute renal failure 0 (0.0) 3 (4.2) 3 (1.9) .06
Hematoma 1 (1.2) 6 (8.4) 7 (4.5) .03
Embolization 5 (6.0) 10 (14.1) 15 (9.7) .09
CDT, Catheter-directed thrombolysis; PMT, pharmacomechanical
thrombolysis.
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tion was performed in 297 patients, for a total of 444
patients treated for ALI.
Patients
Table I shows the baseline patient demographics and
comorbidities. Patients in the CDT and PMT groups were
similar in terms of their baseline characteristics. Details on
previous revascularization are also presented.
Initial presentation
Out of the 154 limbs treated, 110 had undergone
previous ipsilateral revascularization. The most common
causes for ALI were failed bypass, failed stent, and in situ
thrombosis (Table II). Less common causes were emboli-
zation and thrombosed popliteal aneurysm. There was no
signiﬁcant difference between CDT and PMT groups in
terms of etiology. The majority of cases presented with
a Rutherford score of IIa (70.1%). Fewer patients pre-
sented with Rutherford class I (9.7%) and class IIb
(20.1%). There was no signiﬁcant difference between the
two groups in patient distribution among the Rutherford
categories.
Technical success
Technical success was achieved in 129 cases (83.8%).
In the CDT group, technical success was achieved in 65
cases (78.3%) compared with 64 cases (90.1%) in the
PMT group (P ¼ .047). Of the 25 technical failures, one
was treated with observation only, 13 received successful
bypass surgery, 10 required an amputation, and 4 died.
Technical failure was caused by inadequate response to lytic
agent in 21 cases (84.0%), intraoperative bleeding events in
3 cases (12%), and failure to cross the thrombosed vessel in
1 case (4.0%). Adjuvant revascularization procedures were
required in 89.0% of cases. These procedures were endo-
vascular (68.8%), open (11.0%), or hybrid (9.1%) in nature.
The mean duration of lysis was similar between the CDT
group and the 56 cases in the PMT group that requiredadjunctive CDT (CDT, 25.5 hours; PMT, 23.6 hours;
P ¼ .445). The overall mean SVS runoff score decreased
from 13.42 preintervention to 7.43 postintervention,
with no signiﬁcant difference between the CDT and
PMT groups.
Complications
Procedural complications included systemic bleeding
(5.2%), access-site hematoma (4.5%), and acute renal
failure (1.9%; Table III). Bleeding events consisted of three
lower GI bleeds, one upper GI bleed, three retroperitoneal
bleeds, and one brainstem hemorrhage. Unplanned
delayed fasciotomy for compartment syndrome was
required in 3.2% of cases. Distal embolization or clot exten-
sion occurred in 9.7% of cases (CDT, 6.0%; PMT, 14.1%;
P ¼ .093). This number included patients with clinically
signiﬁcant distal embolization who required either adjunc-
tive CDT or surgical conversion. It also included angio-
graphically determined embolization without clinical
sequelae that was managed expectantly. The overall
30-day mortality rate was 5.2% (CDT, 4.8%; PMT, 5.6%;
P ¼ .82). The most common known cause of 30-day
mortality was systemic bleeding in each group. Of the
bleeds described above, the brainstem hemorrhage, upper
GI bleed, and one of the retroperitoneal bleeds proved
fatal. Other causes of death included cardiovascular events.
Limb loss
The overall major amputation rate was 15% with no
signiﬁcant difference between the CDT and PMT groups.
The periprocedural major amputation rate was 6.4% at
30 days, which increased to 13.0% at 12 months, with no
signiﬁcant difference between the CDT and PMT groups.
Patency
Mean follow-up was 15.20 months (range, 0.56-
56.84 months). The overall primary patency (Fig 1) was
56% and 46% at 12 and 24 months, respectively, with no
signiﬁcant difference between the two groups (CDT, 54%
and 41%; PMT, 59% and 50%, respectively; P ¼ .524).
Overall primary assisted patency (Fig 2) at 12 and
24 months was 66% and 55%, respectively (CDT, 62%
and 50%; PMT, 70% and 60%; P ¼ .288). Overall
secondary patency (Fig 3) at 12 and 24 months was 81%
and 71%, respectively (CDT, 74% and 62%; PMT, 87%
and 80%; P ¼ .197).
Fig 1. Kaplan-Meier survival curve for primary patency (catheter-
directed thrombolysis [CDT], blue; pharmacomechanical throm-
bolysis [PMT], red).
Fig 2. Kaplan-Meier survival curve for primary assisted patency
(catheter-directed thrombolysis [CDT], blue; pharmacomechanical
thrombolysis [PMT], red).
Fig 3. Kaplan-Meier survival curve for secondary patency (cath-
eter-directed thrombolysis [CDT], blue; pharmacomechanical
thrombolysis [PMT], red).
Table IV. Multivariable analysis of limb loss
Variable HR 95% CI P value
PMT 0.506 0.23-1.13 .097
Current smokera 0.277 0.08-0.90 .014
Former smokera 1.414 0.52-3.84
ESRD/dialysis 8.563 2.61-28.06 <.001
One patent pedal outﬂow
vesselb
0.205 0.08-0.55 <.001
Two patent pedal outﬂow
vesselsb
0.074 0.02-0.34
CI, Conﬁdence interval; ESRD, end-stage renal disease; HR, hazard ratio;
PMT, pharmacomechanical thrombolysis.
aCompared with never smoker.
bCompared with zero patent pedal outﬂow vessels.
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Overall survival rate was similar between the two
groups (P ¼ .341). Survival at 1 year was 84% (CDT,
82%; PMT, 86%). Survival at 2 years was 73% (CDT,
67%; PMT, 81%).
Multivariable analysis
Limb loss. The use of PMT was not a signiﬁcant
predictor (hazard ratio [HR], 0.506; P ¼ .097) of limb
loss, suggesting that CDT and PMT confer a similar risk
of amputation (Table IV). Patients with end-stage renal
disease (ESRD) were at an increased risk of amputation
(HR, 8.563; P < .001). Patients with one patent pedal
outﬂow vessel on presentation (dorsalis pedis, posterior
tibial, or peroneal collateral) experienced decreased risk of
limb loss when compared with patients with no patent
pedal outﬂow vessels (HR, 0.205; P < .001). An incre-
mental positive effect was observed as patients with two ormore patent pedal outﬂow vessels had an even further
decreased risk of amputation (HR, 0.074; P < .001). The
risk of limb loss was not different by type of vessel treated
with thrombolysis (native artery, vein graft, prosthetic
graft), and this was also comparable between the two
groups (Fig 4).
Patency. The use of PMT was again not a signiﬁcant
predictor of loss of primary patency (HR, 0.85; P ¼ .525;
Table V). Patients with ESRD experienced an increased
risk of loss of primary patency (HR, 8.174; P < .001).
Higher preprocedure SVS runoff score (HR, 1.097; P ¼
.008) and presentation with a thrombosed stent (HR,
2.815; P ¼ .002) were both associated with an increased
risk of loss of primary patency.
Similarly, the use of PMT was not a predictor of loss of
secondary patency. Age (HR, 1.047; P ¼ .002) and ESRD
(HR, 26.258; P < .001) were the only signiﬁcant predic-
tors of loss of secondary patency.
Technical success. The use of PMT was a signiﬁcant
predictor of technical success (odds ratio [OR], 2.67;
P ¼ .046). The presence of patent pedal outﬂow vessels
also predicted technical success when compared with
patients with no patent pedal vessels (one pedal vessel:
Fig 4. Kaplan-Meier survival curve for major amputation
comparing the three different vessel types lysed (native artery, blue;
vein graft, red; prosthetic graft, green).
Table V. Multivariable analysis of loss of primary patency
Variable HR 95% CI P value
PMT 0.85 0.52-1.40 .525
ESRD/dialysis 8.174 2.64-25.27 <.001
Runoff score (pre) 1.097 1.03-1.18 .008
Stent thrombosis 2.815 1.46-5.45 .002
CI, Conﬁdence interval; ESRD, end-stage renal disease; HR, hazard ratio;
PMT, pharmacomechanical thrombolysis.
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.0125; three pedal vessels: OR, 3.48; P ¼ .0125). No other
variables were found to predict technical success or failure,
including Rutherford score, pedal outﬂow, runoff scores,
and ischemia etiology.
Mortality. Survival analysis of mortality found age to
be the only signiﬁcant predictor of death (HR, 1.058;
P < .001).DISCUSSION
The results of our study reafﬁrm the belief that throm-
bolysis remains a safe and effective alternative to surgery for
treating ALI. Amputation and mortality rates from our
study are comparable to historical controls. The overall
30-day mortality rate of 5.2% seen in this study is similar
to the corresponding rates (4.9% and 4.0% in the surgical
and thrombolysis groups, respectively) of the STILE trial.1
It is also similar to the mortality rates at discharge in the
TOPAS trial (5.9% and 8.8% in the surgery and thrombol-
ysis groups, respectively).2 The current 1-month major
amputation rate of 6.4% is also almost identical to the
1-month major amputation rate of 6.3% demonstrated
by the STILE trial in surgical patients and slightly higher
than the 5.2% major amputation rate in the thrombolysis
patients.1 The 1-year amputation rate of 13.0% in the
present study compares favorably with the 1-yearamputation rate of 30.0% shown by Comerota et al in
patients treated surgically for lower extremity bypass graft
failure.8 Our 1-year amputation-free survival of 74.7%
compares well with the 1-year amputation-free survival of
69.9% seen in patients randomized to surgery in the
TOPAS trial.2
Our technical success rate of 84% is similar to the re-
ported rates in previous studies investigating ALI and
thrombolysis.2,9,10 Almost half (46%) of the technical fail-
ures in this study were able to be salvaged with subsequent
bypass, indicating that a failure of thrombolysis does not
necessarily prevent a successful surgical intervention or
condemn the patient to an amputation. These favorable
comparisons to historical surgical and endovascular
controls demonstrate the efﬁcacy of thrombolysis using
current endovascular techniques.
One important ﬁnding of our study was the lack of
signiﬁcant association between PMT and any of the adverse
end points. The outcomes of the CDT and PMT groups in
terms of amputation, patency rates, and mortality were
similar between the two groups. This is consistent with
a study by Kashyap et al that found no statistically signiﬁ-
cant effect of the use of PMT on 30-day amputation rates.9
These ﬁndings suggest that PMT can be safely utilized in
the setting of ALI, including patients with thrombosed
stents and bypass grafts. In this series, PMT alone was
used as a one-session therapy in 10% of patients, indicating
that this approach allows for expedited therapy for selected
patients with ALI. Adjunctive and primary CDT were
commonly used, however, indicating that CDT still has
an important role to play in the treatment of ALI.
While use of PMTwas not a predictor of adverse events,
it was an independent predictor of technical success, result-
ing in restoration of inline ﬂow to the foot with no need for
surgical conversion. This ﬁnding has to be cautiously inter-
preted, however, given the limited sample size, and given
the higher incidence of embolic complications seen with
PMT, although this did not reach statistical signiﬁcance.
The higher technical success rate seen in the PMT group
primarily indicates the safety of this approach in the setting
of ALI. Nevertheless, given the heterogeneity in patient
selection based on clot age and that PMT was used in
patients felt likely to favorably respond to lytic therapy, it
is difﬁcult to preferentially recommend the use of PMT
over CDT based on this ﬁnding. In addition, while the
use of PMT was shown to decrease the need for surgery
when compared with CDT and restore ﬂow quicker in
patients who did not require adjunctive lytic infusion, it
did not seem to offer any beneﬁt in terms of amputation
rate and survival. Although the majority of patients received
a heparin infusion ipsilateral to the ischemic limb through
sheath access, it is unlikely that this low-dose infusion had
any impact on procedural success.
One consistent ﬁnding of our study was that patients
with ESRD fared signiﬁcantly worse for almost all of the
end points evaluated. Those with ESRD had an increased
risk (ranging from 6- to 26-fold) of amputation, and loss
of primary, primary assisted, and secondary patency. This
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a patient population with notoriously diffuse vascular
disease, small vessel disease, and challenging limb salvage.
Neither the STILE nor TOPAS trials analyzed the
outcomes of patients with baseline ESRD for comparison.
These ﬁndings suggest that patients with ESRD are poor
candidates for thrombolysis, and one may speculate that
alternative initial revascularization strategies, such as open
surgical treatment, may be beneﬁcial. Similarly, patients
with poor pedal outﬂow experienced an increased risk of
limb loss despite pedal lysis. Although surgical thrombec-
tomy can be attempted in those patients, limb salvage
with any therapy, surgical or endovascular, will likely be
challenging.
The result that increased pedal runoff on presentation
afforded protection against limb loss and was a predictor
of technical success is intuitive. The stepwise fashion in
which increased pedal outﬂow protected against amputa-
tion, with three outﬂow vessels protecting more than two
vessels, and two vessels protecting more than one, is partic-
ularly compelling. While inline ﬂow to the foot with one
vessel is often the aim of revascularization, the above results
suggest that pedal outﬂow with more than one vessel could
produce better outcomes, and may be a more appropriate
goal for revascularization.
Another interesting ﬁnding of our study was the lack of
signiﬁcant difference in amputation rates between the three
different vessel types treated (native artery, vein graft, pros-
thetic graft). This is contrary to other studies, which have
reported increased major morbidities in patients with pros-
thetic grafts who undergo thrombolysis.8,11,12 In addition,
PMT was more frequently used than CDT for thrombosed
prosthetic bypass grafts (out of 26 patients with a failed
bypass treated with PMT, 17 had a failed prosthetic bypass)
and resulted in signiﬁcantly superior technical success with
similar rates of adverse events. This suggests that the pres-
ence of a prosthetic graft alone should not dissuade from
treating ALI with thrombolysis, speciﬁcally with PMT, as
the outcomes in these patients were no different from those
with vein graft or native vessel thrombosis. Also, Ruther-
ford score was not a signiﬁcant predictor of any adverse
outcomes, indicating that the 31 limbs presenting with
Rutherford score IIb did not fare worse with thrombolysis
than the limbs with milder ischemia on presentation. This
suggests that limbs with Rutherford IIb ischemia can be
safely treated with endovascular intervention, which may
be an attractive option for patients at high risk for surgery
due to prohibitive medical risk or anatomic factors.
One of the main limitations of our study was the fact
that we relied on historical controls data from STILE and
TOPAS to compare to contemporary endovascular
outcomes. It is possible that outcomes could have been
confounded by changes in medical therapy as well as lytic
agents. As such, we do have a comparative effectiveness
study underway of open vs endovascular treatment for
ALI, which will allow us to compare contemporaneous
endovascular and surgical series stratiﬁed by the severity
of limb ischemia on presentation.Also, time from onset of ischemia to initiation of
therapy was not consistently available for analysis. This vari-
able can certainly affect the reported outcomes of this study
but was not possible to study.
An additional limitation of our study is the fact that
most patients selected for endovascular intervention did
not have advanced limb ischemia, as patients who require
more immediate revascularization are more commonly
treated with open techniques in accordance with current
clinical practice. This could have affected our comparison
to historical surgical controls. However, historical controls
should have been comparable in terms of the severity of
ischemia on presentation since subjects were typically
excluded from randomization in the setting of severe
ALI. Also, patients who received a combination of CDT
and PMT, and those who received PMT only were treated
as equal, given the possible risk of adverse events with PMT
performed at any time and the small sample size of the
subgroup of PMT alone. Initial CDT could have decreased
the risk of embolization with subsequent PMT or increased
the bleeding risk. However, it is difﬁcult to comment on
the safety of PMT alone, given the small sample size.
CONCLUSIONS
In spite of these limitations, we were able to conclude
that thrombolysis using tPA remains an effective treatment
option for patients presenting with lower extremity mild
and moderate ALI by Rutherford classiﬁcation, and CDT
and PMT demonstrate equivalent limb salvage, patency
rates, and mortality. However, patients with ESRD or
poor pedal outﬂow may beneﬁt from alternative revascular-
ization strategies. PMT alone can be used as a standalone
therapy, speciﬁcally in ALI patients with thrombosed stents
or prosthetic bypass grafts, and can achieve improved tech-
nical success over CDT. The duration of thrombolysis can
also be shortened in patients with ALI with PMT as stand-
alone or adjunctive therapy with CDT, with no periopera-
tive or long-term sequelae.
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